US Patent Issued to Radionetics Oncology on Jan. 13 for "Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof" (California Inventors)

ALEXANDRIA, Va., Jan. 13 -- United States Patent no. 12,521,455, issued on Jan. 13, was assigned to Radionetics Oncology Inc. (San Diego).

"Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof" was invented by Junjie Liu (San Diego), Yunfei Zhu (San Diego), Yifeng Xiong (San Diego) and Jian Zhao (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are radiotherapeutics that target tumor cells expressing the Kisspeptin receptor (KISS1R) and their use in the treatment and/or diagnosis of cancer."

The patent was filed on April 7, 2025, under Application No. 19/172,351.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netac...